KRAS and colorectal carcinoma: Compared to control, ON123300 selectively inhibited the growth of tumors in both KRAS-mutant HCT116-derived and CRC chemoresistant PDTXs (Fig. 1i) without adverse side effects (Fig. s8b–d).